The impotence of price controls: Failed attempts to constrain pharmaceutical expenditures in Greece

Health Policy

Volumn 101, Issue 2, 2011, Pages 162-171

  Lambrelli, Dimitra ^a   O'Donnell, Owen ^a,b  

^a UNIVERSITY OF MACEDONIA   (Greece)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Pharmaceutical expenditures; Pharmaceuticals; Prescribing; Price controls

Indexed keywords

ARTICLE; COST CONTROL; DRUG COST; DRUG INDUSTRY; GREECE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; PRESCRIPTION; SOCIAL INSURANCE;

COST CONTROL; DRUG COSTS; GREECE; HEALTH EXPENDITURES; PHYSICIAN'S PRACTICE PATTERNS; PROGRAM EVALUATION;

EID: 79958000078     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.08.023     Document Type: Article

References (53)

1. OECD Health Data; 2009.
2. Tragakis E, Polyzos N. Health Care Systems in Transition, Greece; 1996.
3. Geitona M., Zavras D., Hatzikou M., Kyriopoulos J. Generics market in Greece: the pharmaceutical industry's beliefs. Health Policy 2006, 79:35-48.
4. Kousoulakou H, Fragoulakis V. Pharmaceutical market in Greece. Foundation for Economic and Industrial Research (IOBE), Athens; 2004.
5. European Federation of Pharmaceutical Industries and Associations (EFPIA). The pharmaceutical industry in figures. Key data 2007 update, Brussels; 2007.
6. Greek Official Gazette, Law No. 3457, reform of the system of pharmaceutical care. Bulletin 2006;1(93) [in Greek].
7. Paterson I, Fink M, Ogus A. Economic impact of regulation in the field of liberal professions in different member states. Study for the European Commission, DG Competition; 2003. p. 1-277.
8. Carlsen F, Grytten J. More physicians: improved availability or induced demand? Health Economics 7(September (6));1998:495-508.
9. Birch S. The identification of supplier-inducement in a fixed price system of health care provision. Journal of Health Economics 1988, 7:129-150.
10. Madden D., Nolan A., Nolan B. GP reimbursement and visiting bahaviour in Ireland. Health Economics 2005, 14:1047-1060.
11. AESGP. AESGP facts & figures. Available at: ; 2008 [accessed 12..12.08]. http://www.aesgp.be/publications/Facts-Figures.asp.
12. Silvio G. The drug market in four European countries. Pharmacoeconomics 1998, 14(Suppl. 1):69-79.
13. Lopez-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000, 54(2):87-123.
14. Ioannides-Demos L.L., Ibrahim J.E., McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002, 20(9):577-591.
15. Mrazek M.F. Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Medical Journal 2002, 43(August (4)):453-461.
16. Ess S.M., Schneeweiss S., Szucs T.D. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003, 21(2):89-103.
17. Karokis A, Christodoulopoulou A, Tsiaras T, Mossialos E. Pharmaceutical price controls and positive drug list effects on total and social insurance pharmaceutical expenditure. In: ISPOR conference, Amsterdam; 2000.
18. Lopatatzidis A, Hatziandreou E, Nektarios M. Assessment of the effects of a positive drug list in primary care prescribing in Greece. Social Security Fund, Athens; 2001.
19. Volker U., Eberhard W. Healthcare reform and expenditure on drugs the German situation. Pharmacoeconomics 1996, 10(Suppl. 2):81-88.
20. Ghislandi S., Krulichova I., Garattini L. Pharmaceutical policy in Italy: towards a structural change?. Health Policy 2005, 72:53-63.
21. Gosden T., Torgerson D.J. The effect of fund holding on prescribing and referral costs: a review of the evidence. Health Policy 1997, 40:103-114.
22. Paris V. Pharmaceutical regulation in France 1980-2003. International Journal of Health Planning and Management 2005, 20:307-328.
23. van de Wolf1 P., Brouwer W.B., Rutten F.F. Regulating the Dutch pharmaceutical market: improving efficiency or controlling costs?. International Journal of Health Planning and Management 2005, 20:351-374.
24. Mossialos E, Srivastava D. Pharmaceutical policies in Finland: challenges and opportunities. Ministry of Health and Social Affairs (Finland) and European Observatory on Health Systems and Policies. Copenhagen: World Health Organization; 2008.
25. Barros P., de Almeida Simões J. Portugal: Health system review. Health Systems in Transition 2007, 9(5):1-140.
26. European Federation of Pharmaceutical Industries and Associations (EFPIA). The pharmaceutical industry in figures no. Key data. Brussels, Belgium: European Federation of Pharmaceutical Industries and Associations; 2007.
27. Simoens S, De Coster S. Sustaining generic medicines markets in Europe, Research Centre for Pharmaceutical Care and Pharmaco-economics, University of Leuven. Available at: ; 2006. http://www.egagenerics.com/doc/simoens-report_2006-04.pdf.
28. Pharmaceutical Pricing and Reimbursement Information (PPRI). GOG/OBIG in cooperation with the WHO, Vienna. http://ppri.goeg.at/Downloads/Publications/PPRI_Report_final.pdf.
29. Sandier S, Paris V, Polton D. Health care systems in transition: France. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2004.
30. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. OECD Labour Market and Social Policy Occasional Papers; 2000.
31. Dickson M., Redwood H. Pharmaceutical reference prices: how do they work in practice?. Pharmacoeconomics 1998, 14(5):471-479.
32. Terzi G. Comparative analysis of cost-containment policies for pharmaceutical expenditures in European countries. Pharmaceutical policy and economics in Greece 1999, 64-88. Themelio, Athens, [in Greek]. M. Geitona, J. Kyriopoulos (Eds.).
33. Contiades X., Golna C., Souliotis K. Pharmaceutical regulation in Greece at the crossroad of change: economics, political and constitutional. Health Policy 2007, 82:116-129.
34. Kousoulakou H. Pharmaceutical market in Greece. Foundation for Economic and Industrial Research (IOBE), Athens; 2006.
35. Mrazek M., Mossialos E. Regulating pharmaceutical prices in the European Union. European observatory on health systems and policies series ed. 2004, 136-151. Open University Press, England, UK. E. Mossialos, M. Mrazek, T. Walley (Eds.).
36. Kontozamanis V. The Greek Pharmaceutical Market, Athens; 2001.
37. Souliotis K. Analysis of health care expenditures in Greece 1989-2000. Methodological clarifications and conclusions on the Greek health care system. Health care expenditure in Greece: methodological issues and consequences on health policy 2002, Papazisi, Athens. K. Souliotis, J. Kyriopoulos (Eds.).
38. Gerdtham U.G., Johannesson M., Jonsson B. Drug expenditure and new drug introductions: the Swedish experience. Pharmacoeconomics 1993, 4(September (3)):215-225.
39. Dubois R.W., Chawla A.J., Neslusan C.A., Smith M.W., Wade S. Explaining drug spending trends: does perception match reality?. Health Affairs (Millwood) 2000, 19(March-April (2)):231-239.
40. Berndt E., Griliches Z., Rosett J. Auditing the Producer Price Index: micro evidence from prescription pharmaceutical Preparations. Journal of Business and Economic Statistics 1993, 11(3):251-264.
41. Gerdtham U.G. Equity in health care utilization: further tests based on hurdle models and Swedish micro data. Health Economics 1997, 6(3):303-319.
42. Gerdtham U.G., Johannesson M., Gunnarsson B., Marcusson M., Henriksson F. The effect of changes in treatment patterns on drug expenditure. Pharmacoeconomics 1998, 13(1 Pt 2):127-134.
43. Morgan S.G., Agnew J.D., Barer M.L. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy 2004, 68(3):299-307.
44. Peura S, Rajaniemi S, Kurkijárvi U. Pharmaceutical pricing and reimbursement information project. Pharma Profile, Finland. Austria: ÖBIG; 2007.
45. de Swaef A, Antonissen Y. Pharmaceutical pricing and reimbursement information. Pharma Profile, Belgium. Austria: ÖBIG; 2007.
46. Teixeira I, Vieira I. Pharmaceutical pricing and reimbursement information. Pharma Profile, Portugal. Austria: ÖBIG; 2008.
47. Strandberg-Larsen M., Bernt Nielsen M., Vallgarda S., Krasnik A., Vrangbaek K. Denmark: health system review. Health Systems in Transition 2007, 9(6):1-164.
48. Van Tielen R., Peys F., Genaert J. The demographic impact on ambulatory pharmaceutical expenditure in Belgium. Health Policy 1998, 45(1):1-14.
49. Windmeijer F., de Laat E., Douven R., Mot E. Pharmaceutical promotion and GP prescription behaviour. Health Economics 2000, 15(1):5-18.
50. Jonsson B. Pricing and reimbursement of pharmaceuticals in Sweden. Pharmacoeconomics 1994, 6(Suppl. 1):51-60.
51. Marchant N. Drivers of the growth in medicines Expenditure 1997, Office of Health Economics, London, UK.
52. Lopez Batista J., Mossialos E. Pharmaceutical expenditure in Spain: cost and control. International Journal of Health Services 2000, 30(3):597-616.
53. Gerdtham U.G., Lundin D. Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics 2004, 22(1):29-42.